Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Sponsor
RenJi Hospital
Study ID
NCT05779644
Status
Unknown

Conditions

  • Abdominal Fat
  • Diabetes Mellitus, Type 2
  • Metabolism Disorder, Glucose
  • Metabolism Disorder, Lipid
  • Metformin
  • Non-Alcoholic Fatty Liver Disease
  • Obesity, Abdominal

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Liraglutide is injected once a day.
  • Semaglutide — DRUG
    Semaglutide is injected once a week.
  • Metformin — DRUG
    Metformin is taken orally daily.

Study Details

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

Key Dates

Start date
Feb 23, 2023
Status verified
May 2023
Primary completion
Feb 23, 2025
Completion
Feb 23, 2025

Study Design

Enrollment
300 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide group
    Liraglutide is injected once a day.
  • Experimental: Semaglutide group
    Semaglutide is injected once a week.
  • Experimental: Metformin group
    Metformin is taken orally daily.

Primary Outcome Measure

Blood glucose [ Time Frame: The twelfth week of treatment ]

Related Studies